Relay Therapeutics Inc (NASDAQ: RLAY) kicked off on Tuesday, up 1.67% from the previous trading day ,before settling in for the closing price of $7.19. Over the past 52 weeks, RLAY has traded in a range of $5.95-$19.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 319.82% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -3.44%. With a float of $92.21 million, this company’s outstanding shares have now reached $127.46 million.
In an organization with 323 employees, it is important to assess its efficiency.
Relay Therapeutics Inc (RLAY) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relay Therapeutics Inc is 29.71%, while institutional ownership is 71.70%. The most recent insider transaction that took place on Mar 27 ’24, was worth 5,890. In this transaction President, R&D of this company sold 765 shares at a rate of $7.70, taking the stock ownership to the 530,113 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Financial Officer sold 348 for $7.70, making the entire transaction worth $2,680. This insider now owns 341,498 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.67 earnings per share (EPS), higher than consensus estimate (set at -$0.73) by $0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.44% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Take a look at Relay Therapeutics Inc’s (RLAY) current performance indicators. Last quarter, stock had a quick ratio of 25.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.79, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -2.83 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.31 million. That was better than the volume of 1.11 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 22.82%. Additionally, its Average True Range was 0.49.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 10.39%, which indicates a significant decrease from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.26% in the past 14 days, which was lower than the 60.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.01, while its 200-day Moving Average is $9.65. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $7.42. Second resistance stands at $7.53. The third major resistance level sits at $7.67. If the price goes on to break the first support level at $7.16, it is likely to go to the next support level at $7.02. Assuming the price breaks the second support level, the third support level stands at $6.91.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
The company with the Market Capitalisation of 958.93 million has total of 131,179K Shares Outstanding. Its annual sales at the moment are 25,550 K in contrast with the sum of -341,970 K annual income. Company’s last quarter sales were recorded 25,200 K and last quarter income was -65,730 K.
